← Leaderboards
Juan C Osorio
Sloan-Kettering Inst Can Research
$605,356
Attributed
$605,356
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $151.3K · FY2022–25$200K$150K$100K$50K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$605,356 · 1
By mechanism
K08$605,356 · 1
Top collaborators
No co-investigators on record.
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Brian Matthew Zeglis$6,881,872
Others in their field
Other Rising Stars on “Consensus”
- Torben Schiffner · Vanderbilt University$3,383,634
- David Michael Keith Knapp · University Of Southern California$3,295,669
- Talea Cornelius · Columbia University Health Sciences$3,273,481
- Emil Schueler · University Of Tx Md Anderson Can Ctr$3,198,082
- Victoria Eleanor Johnson · University Of Pennsylvania$3,102,638
- Augustus Shanahan · Piccolo Medical, Inc.$3,026,932
Research focus
ConsensusEarly Phase Clinical TrialClinicClinical TrialsDevelopment PlansAntitumor EffectAntitumor ResponseAnti-Cd47Advisory CommitteesBlocking AntibodiesDendritic CellsCancer ImmunotherapyCancer TherapyCancer TypeCareerCareer DevelopmentCd47 GeneCd47-Sirpî±BindingCd8-Positive T-LymphocytesCellsCell Surface ReceptorsAntibodiesEating
Grant awards (4)
Role of Fc Receptors in the Therapeutic Activity of Antibodies Targeting the CD47-SIRP-alpha axis$151,339
K08 · FY2025 · CA · contact PI
Role of Fc Receptors in the Therapeutic Activity of Antibodies Targeting the CD47-SIRP-alpha axis$151,339
K08 · FY2024 · CA · contact PI
Role of Fc Receptors in the Therapeutic Activity of Antibodies Targeting the CD47-SIRP-alpha axis$151,339
K08 · FY2023 · CA · contact PI
Role of Fc Receptors in the Therapeutic Activity of Antibodies Targeting the CD47-SIRP-alpha axis$151,339
K08 · FY2022 · CA · contact PI